Printer Friendly

DISEASE DETECTION INTERNATIONAL INC. ANNOUNCES FIRST QUARTER 1992 PROFITS AND 1991 YEAR-END LOSS REDUCTION

 DISEASE DETECTION INTERNATIONAL INC. ANNOUNCES FIRST QUARTER 1992
 PROFITS AND 1991 YEAR-END LOSS REDUCTION
 IRVINE, Calif., May 8 /PRNewswire/ -- Disease Detection International Inc. (DDI) (NASDAQ: DDII) announced 1992 first quarter revenues of $626,177 and a net profit of $193,548. This compares to first quarter 1991 revenues of $159,080 and a loss of ($416,760). In making the announcement, DDI's president and chief executive officer, H. Thad Morris, explained the dramatic turn-around in the financial results were attributed to several one-time events related to changes in the company's license agreements with Meridian Diagnostics of Cincinnati. Sales revenues related to the company's on-going business were $175,013, compared to $151,861 for the prior period, reflecting a 15 percent increase.
 In the company's annual 10(k) filing with the Securities and Exchange Commission, it reported 1991 total revenues were $1,016,687, compared to 1990's revenue of $1,312,494; however, the company's net loss decreased in 1991 to $1,291,195, compared to a loss of $2,689,623 in 1990. Morris commented that "while the company was still not profitable operationally, Disease Detection International Inc., is beginning to recognize the benefits of its restructuring and down-sizing which followed the bankruptcy in June of 1990, of Access Medical Systems Inc., the company's largest distributor.
 Morris commented further that DDI's future is still uncertain but that he is optimistic that the company can return to sound financial footing in light of several agreements the company has executed in the fourth quarter of 1991 and the first quarter of 1992.
 In November 1991, the company announced a three-year, worldwide non- exclusive distribution agreement with Ciba Corning Diagnostics ("Corning"). The company expects to begin initial shipments to Corning by late second quarter. In addition, Disease Detection International Inc. announced in February, that it had reached a $5.6 million agreement with Saliva Research Laboratories, to provide, among other things, an equity investment in DDI for at least $2,000,000 in cash.
 In February, Saliva Research Laboratories provided $200,000 in the form of a bridge loan to the company and recently agreed to convert the loan to equity and provide an additional $300,000 cash for stock, to accelerate its equity investment. The companies plan to close the total transaction before the end of July, subject to certain conditions of closing.
 Morris also announced that the company plans to begin commercial production in the third quarter of its new, ImmunoCard(R) 1-Step, pregnancy test, previously approved by the Food and Drug Administration (FDA, 510(k) pre-market approval). "While we have limited resources, there is a growing demand among our established distribution channels for this simplified version of our two-step, four-minute test. Since the introduction of the two-step test, Disease Detection has sold approximately 1,000,000 of its pregnancy tests in the professional markets. The company also plans to submit the ImmunoCard pregnancy test to the FDA for over-the-counter (OTC) approvals, which if granted, would provide a retail market for the company's products.
 The company also provided an update on its rapid, eight-minute, whole blood, AIDS test. Morris stated that the company's SeroCard(R) HIV test kit, which has received very favorable, pre-clinical results in Sweden and Thailand, is restricted from sale or export until the company enters formal clinical trials with the U.S. FDA. He did say that the company is exploring the possibility of manufacturing in Mexico or Ireland in order to expedite international sales, pending the receipt of the necessary funding to submit the SeroCard HIV test to the FDA. "Several U.S. diagnostic companies are manufacturing and marketing their more complex versions of AIDS test kits in foreign markets while completing formal FDA studies in the United States and we could benefit from a similar strategy."
 While the company doesn't expect to submit its AIDS test to the FDA until it receives the anticipated funding from Saliva Research Laboratories, its scientists are collaborating with Saliva Research and Trinity Biotech plc of Dublin, Ireland, to validate the use of saliva as a test specimen on the SeroCard device. The use of saliva as a specimen has many inherent advantages over the use of blood or blood components in a variety of clinical settings, not the least of which, is the reduced exposure for health-care providers. DDI and Trinity's scientists have successfully demonstrated that the SeroCard can be adapted to accept a saliva sample. Trinity Biotech plc will carry on with the research and development of the saliva test and perform the pre-clinical studies leading to commercialization of the SalivaCard HIV product.
 Disease Detection International Inc. develops, manufactures and markets a variety of patented, rapid, immunological test kits in the field of infectious and sexually transmitted diseases.
 -0- 5/8/92
 /CONTACT: H. Thad Morris, president and CEO of Disease Detection International, 714-753-1190/
 (DDII) CO: Disease Detection International Inc. ST: California IN: HEA SU: ERN


JL-EH -- LA011 -- 7949 05/08/92 08:46 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 8, 1992
Words:827
Previous Article:CITICORP AWARDS MCI $250 MILLION AGREEMENT TO PROVIDE TELECOMMUNICATIONS SERVICES; MCI'S LARGEST COMMERCIAL AGREEMENT
Next Article:LIZ CLAIBORNE OFFERS TO PURCHASE ASSETS OF RUSS TOGS
Topics:


Related Articles
QUIDEL REPORTS INCREASED FOURTH QUARTER SALES AND FIRST FULL-YEAR OF PROFITABILITY
BAYPORT RESTAURANT GROUP REPORTS 400 PERCENT INCREASE IN PROFITS FOR FIRST QUARTER ENDED MARCH 30
INTERFERON SCIENCES, INC. REPORTS FIRST QUARTER RESULTS
MEDCROSS REPORTS $61,715 PRE-TAX INCOME FOR FIRST QUARTER
PLY GEM POSTS FIRST QUARTER RESULTS; RECORD FIRST QUARTER SALES REDUCED NORMAL SEASONAL LOSS
BOSTON PACIFIC MEDICAL REPORTS FIRST QUARTER 1992 RESULTS; SALES INCREASE 148 PERCENT; GROSS PROFITS ACHIEVED
DISEASE DETECTION INTERNATIONAL INC. COMPLETES $4.5-MILLION FINANCIAL RESTRUCTURING
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION ANNOUNCES 1992 YEAR END AND FOURTH QUARTER FINANCIAL RESULTS
DISEASE DETECTION INTERNATIONAL REPORTS RECORD REVENUES AND PROFITS FOR FISCAL 1992 AND SIGNIFICANT FORECASTS FOR 1993 AND BEYOND
IMEX MEDICAL SYSTEMS REPORTS SALES AND EARNINGS FOR 1993 THIRD QUARTER

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters